IMPACT OF ABCB1 AND CES1 GENETIC POLYMORPHISMS ON TROUGH STEADY-STATE DABIGATRAN CONCENTRATIONS IN PATIENTS AFTER ENDOPROSTHESIS OF KNIFE JOIN

IMPACT OF ABCB1 AND CES1 GENETIC POLYMORPHISMS ON TROUGH STEADY-STATE DABIGATRAN CONCENTRATIONS IN PATIENTS AFTER ENDOPROSTHESIS OF KNIFE JOIN

Oral anticoagulants are widely used to prevent thromboembolic events in patients following total knee arthroplasty [1]. The genetic characteristics of patients affect the efficacy and safety of anticoagulants [2]. Dabigatran etexilate is a direct inhibitor of thrombin used as a prophylaxis of venous...

Full description

Bibliographic Details
Main Authors:	D. A. Sychev, A. N. Levanov, T. V. Shelekhova, P. O. Bochkov, N. Р. Denisenko, K. A. Ryzhikova, K. В. Mirzaev, E. A. Grishina, M. A. Gavrilov
Format:	Article
Language:	Russian
Published:	«REMEDIUM GROUP» Ltd. 2018-05-01
Series:	Атеротромбоз
Subjects:	новые пероральные антикоагулянты дабигатран венозные тромбоэмболические осложнения abcb1 ces1 rs4148738 с3435т фармакогенетика
Online Access:	https://www.aterotromboz.ru/jour/article/view/157

Similar Items

APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA
by: D. A. Sychev, et al.
Published: (2015-09-01)

DABIGATRAN ETEXILATE FOR THE TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS
by: N. M. Vorobieva, et al.
Published: (2015-12-01)

Secondary prevention of venous thromboembolic complications. Focus on dabigatrane
by: V.Y. Bogachev, et al.
Published: (2017-12-01)

Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases
by: A. S. Kolbin, et al.
Published: (2023-03-01)

Risk of postoperative venous thromboembolic complication development in elderly patients
by: N. M. Krasnova, et al.
Published: (2018-03-01)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015-12-01)

Антитромботическая терапия при фибрилляции предсердий: новые пероральные антикоагулянты
Published: (2014-12-01)

ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY
by: V. A. Sulimov, et al.
Published: (2015-09-01)

New prospects for assessing the hemostasis system in atrial fibrillation and left atrial appendage thrombosis
by: Z. A. Gebekova, et al.
Published: (2023-01-01)

Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19
by: V. A. Otdelenov, et al.
Published: (2020-10-01)

РИВАРОКСАБАН ПРИ ТРОМБОЗЕ ЛЕВОГО ПРЕДСЕРДИЯ У ПАЦИЕНТА С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ ПРИ ПРОВЕДЕНИИ КАТЕТЕРНОЙ АБЛЯЦИИ
Published: (2014-12-01)

EXTENDED ANTICOAGULANT THERAPYIN PATIENTS, WHO SURVIVED PULMONARY EMBOLISM
by: Natalia M. Vorobieva, et al.
Published: (2018-12-01)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)

PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH CANCER
by: Ju. A. Fedotkina
Published: (2019-06-01)

MODERN APPROACHES TO ANTICOAGULANT THERAPY DURING CATHETER ABLATION TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION
by: E. A. Belikov, et al.
Published: (2015-09-01)

GENETIC FACTORS INFLUENCING THE EFFECTIVENESS AND SAFETY OF LONG-TERM ANTICOAGULANT THERAPY
by: T. V. Burkova, et al.
Published: (2013-06-01)

POTENTIAL OF PHARMACOGENETICS IN THE CORRECTION OF ANTICOAGULANT THERAPY AMONG PATIENT WITH PROSTHETIC HEART VALVES
by: I. Yu. Zhuravleva, et al.
Published: (2013-06-01)

Safety of dabigatran in patients with atrial fibrillation and chronic kidney disease: pharmacokinetic and pharmacogenetic aspects
by: A. I. Skripka, et al.
Published: (2020-01-01)

CОВРЕМЕННЫЕ СТРАТЕГИИ ПРОФИЛАКТИКИ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ
Published: (2016-12-01)

CLINICAL DISCUSSION OF A PATIENT WITH RECURRENT VENOUS THROMBOEMBOLIC COMPLICATIONS
by: A. L. KOMAROV
Published: (2017-12-01)

ON THE SELECTION OF DRUGS DOSAGE REGIMEN
by: E. N. Bochanova
Published: (2015-09-01)

Anticoagulant therapy in patients with atrial fibrillation and an implanted cardiac resynchronization therapy device
by: M. A. Kirgizova, et al.
Published: (2021-05-01)

Elderly patient with atrial fibrillation and coronary risks
by: I. S. Yavelov
Published: (2021-07-01)

The impact of ABCB1 (rs1045642 and rs4148738) and CES1 (rs2244613) gene polymorphisms on dabigatran equilibrium peak concentration in patients after total knee arthroplasty [Corrigendum]
by: Sychev DA, et al.
Published: (2018-09-01)

Multimodal prevention of venous thromboembolic complications after total hip and knee joint endoprosthesis
by: Y. L. Shevchenko, et al.
Published: (2014-12-01)

Comparative clinical and economic evaluation of pharmacogenetic testing application for dabigatran in patients with atrial fibrillation
by: Sh P Abdullaev, et al.
Published: (2019-08-01)

NEW PROSPECTS IN THE SECONDARY PREVENTION OF VENOUS THROMBOSIS
by: P. S. Laguta
Published: (2016-07-01)

EFFICACY AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN THE PREVENTION OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION IN EVERYDAY CLINICAL PRACTICE: FACTS ABOUT RIVAROXABAN
by: I. S. Yavelov
Published: (2016-07-01)

PROPHYLAXIS OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ACTIVE ONCOLOGICAL DISEASE, RECEIVING MEDICAL ANTI-CANCER CHEMOTHERAPY IN OUTPATIENT CONDITIONS. ROLE OF APIXABAN
by: Yu. A. Fedotkina, et al.
Published: (2020-01-01)

Optimization of tactics of the acute varicotrombophlebitis
by: E. P. Krivoschekov, et al.
Published: (2020-12-01)

Risk of venous thromboembolism in patients with pancreatic cancer
by: O. I. Kit, et al.
Published: (2022-06-01)

Enoxaparin in cardiovascular disease: how to improve effectiveness and safety?
by: I. S. Yavelov
Published: (2011-12-01)

COVID-19-associated coagulopathy: review of current recommendations for diagnosis, treatment and prevention
by: K. V. Lobastov, et al.
Published: (2021-01-01)

NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01)

DABIGATRAN AND IDARUZIZUMAB. NEW OPPORTUNITIES FOR IMPROVING PATIENT SAFETY
by: N. A. Novikova, et al.
Published: (2019-06-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Direct oral anticoagulants for electrical cardioversion
by: A. N. Volovchenko, et al.
Published: (2021-07-01)

Problems of selecting an anticoagulant for secondary stroke prevention in patients with atrial fibrillation
by: V. V. Gusev, et al.
Published: (2021-10-01)

БЕЗОПАСНОСТЬ АНТИКОАГУЛЯНТНОЙ ТЕРАПИИ У БОЛЬНЫХ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ. КАК ОБЕСПЕЧИТЬ ПАЦИЕНТУ ОПТИМАЛЬНОЕ ЛЕЧЕНИЕ?
Published: (2014-12-01)